HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

J. Biol. Chem., Vol. 281, Issue 41, 30471-30478, October 13, 2006

This Article Full Text Full Text (PDF) All Versions of this Article: 281/41/30471    most recent M605827200v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Eckman, E. A. Articles by Eckman, C. B. Search for Related Content PubMed PubMed Citation Articles by Eckman, E. A. Articles by Eckman, C. B. Social Bookmarking                      What's this?

Regulation of Steady-state -Amyloid Levels in the Brain by Neprilysin and Endothelin-converting Enzyme but Not Angiotensin-converting Enzyme^*

Elizabeth A. Eckman, Stephanie K. Adams, Frederick J. Troendle, Becky A. Stodola, Murad A. Kahn, Abdul H. Fauq, Hong D. Xiao, Kenneth E. Bernstein, and Christopher B. Eckman¹

From the Department of Neuroscience, Mayo Clinic College of Medicine, Jacksonville, Florida 32224 and the Department of Pathology and Laboratory Medicine, Emory University, Atlanta, Georgia 30322

The deposition of -amyloid in the brain is a pathological hallmark of Alzheimer disease (AD). Normally, the accumulation of -amyloid is prevented in part by the activities of several degradative enzymes, including the endothelin-converting enzymes, neprilysin, insulin-degrading enzyme, and plasmin. Recent reports indicate that another metalloprotease, angiotensin-converting enzyme (ACE), can degrade -amyloid in vitro and in cellular overexpression experiments. In addition, ACE gene variants are linked to AD risk in several populations. Angiotensin-converting enzyme, neprilysin and endothelin-converting enzyme function as vasopeptidases and are the targets of drugs designed to treat cardiovascular disorders, and ACE inhibitors are commonly prescribed. We investigated the potential physiological role of ACE in regulating endogenous brain -amyloid levels for two reasons: first, to determine whether -amyloid degradation might be the mechanism by which ACE is associated with AD, and second, to determine whether ACE inhibitor drugs might block -amyloid degradation in the brain and potentially increase the risk for AD. We analyzed -amyloid accumulation in brains from ACE-deficient mice and in mice treated with ACE inhibitors and found that ACE deficiency did not alter steady-state -amyloid concentration. In contrast, -amyloid levels are significantly elevated in endothelin-converting enzyme and neprilysin knock-out mice, and inhibitors of these enzymes cause a rapid increase in -amyloid concentration in the brain. The results of these studies do not support a physiological role for ACE in the degradation of -amyloid in the brain but confirm roles for endothelin-converting enzyme and neprilysin and indicate that reductions in these enzymes result in additive increases in brain amyloid -peptide levels.

Received for publication, June 19, 2006 , and in revised form, August 9, 2006.

^* This work was supported by NINDS, National Institutes of Health Grants R01NS042192 and R01NS048554 and by the Mayo Foundation for Medical Education and Research. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ To whom correspondence should be addressed: Dept. of Neuroscience, Mayo Clinic College of Medicine, 4500 San Pablo Rd., Jacksonville, FL 32224. Tel.: 904-953-2979; Fax: 904-953-7370; E-mail: eckman{at}mayo.edu.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				J. Kim, V. M. Miller, Y. Levites, K. J. West, C. W. Zwizinski, B. D. Moore, F. J. Troendle, M. Bann, C. Verbeeck, R. W. Price, et al. BRI2 (ITM2b) Inhibits A{beta} Deposition In Vivo J. Neurosci., June 4, 2008; 28(23): 6030 - 6036. [Abstract] [Full Text] [PDF]

				K. M. Elased, T. S. Cunha, F. K. Marcondes, and M. Morris Brain angiotensin-converting enzymes: role of angiotensin-converting enzyme 2 in processing angiotensin II in mice Exp Physiol, May 1, 2008; 93(5): 665 - 675. [Abstract] [Full Text] [PDF]

				I. M. Hajjar, M. Keown, P. Lewis, and A. Almor Angiotensin Converting Enzyme Inhibitors and Cognitive and Functional Decline in Patients with Alzheimer's Disease: An Observational Study American Journal of Alzheimer's Disease and Other Dementias, March 1, 2008; 23(1): 77 - 83. [Abstract] [PDF]

				K. Zou, H. Yamaguchi, H. Akatsu, T. Sakamoto, M. Ko, K. Mizoguchi, J.-S. Gong, W. Yu, T. Yamamoto, K. Kosaka, et al. Angiotensin-Converting Enzyme Converts Amyloid {beta}-Protein 1 42 (A{beta}1 42) to A{beta}1 40, and Its Inhibition Enhances Brain A{beta} Deposition J. Neurosci., August 8, 2007; 27(32): 8628 - 8635. [Abstract] [Full Text] [PDF]

				W. Farris, S. G. Schutz, J. R. Cirrito, G. M. Shankar, X. Sun, A. George, M. A. Leissring, D. M. Walsh, W. Q. Qiu, D. M. Holtzman, et al. Loss of Neprilysin Function Promotes Amyloid Plaque Formation and Causes Cerebral Amyloid Angiopathy Am. J. Pathol., July 1, 2007; 171(1): 241 - 251. [Abstract] [Full Text] [PDF]